Nouman Asif, MD
Hematology & Oncology · Rehoboth Beach, DENPI 1790947174
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.0% of the total across 347 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations. Among hematology & oncology clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 347 payments — averaging $21.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$958
- AstraZeneca$679
- Novartis$486
- E.r. Squibb & Sons, L.L.C.$428
- GSK$390
- AVEO Pharmaceuticals, Inc.$354
- plus $4K from 54 others
What the payments were for
- Food & beverage$7,02393%
- Education$5337%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$7,555 in reported general payments places this provider in the 95th percentile of 26 hematology & oncology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 22 | $343,272 |
| NerlynxNeratinib Maleate | 16 | $338,146 |
| XtandiEnzalutamide | 23 | $325,217 |
| CalquenceAcalabrutinib Maleate | 21 | $324,450 |
| TasignaNilotinib Hcl | 13 | $241,568 |
| PiqrayAlpelisib | 11 | $233,033 |
| Lenalidomide | 16 | $221,736 |
| XareltoRivaroxaban | 109 | $106,094 |
| JakafiRuxolitinib Phosphate | 12 | $100,487 |
| EliquisApixaban | 125 | $86,765 |
| Abiraterone Acetate | 17 | $72,814 |
| Anastrozole | 74 | $2,013 |
| Letrozole | 67 | $1,972 |
| Imatinib Mesylate | 13 | $1,879 |
| Fentanyl | 15 | $1,453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisTasigna, Piqray | $486 | $474,60124 claims |
| Beigene USA, Inc.Brukinsa | $67 | $343,27222 claims |
| Puma Biotechnology, Inc.Nerlynx | $30 | $338,14616 claims |
| Astellas Pharma US IncXtandi | $32 | $325,21723 claims |
| AstraZenecaCalquence | $679 | $324,45021 claims |
| Johnson & JohnsonXarelto | $958 | $106,094109 claims |
| Incyte CorporationJakafi | $104 | $100,48712 claims |
| PfizerEliquis | $231 | $86,765125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 26 hematology & oncology providers in Delaware.
Other hematology & oncology in Rehoboth Beach
- Nisarg DesaiRehoboth Beach$902
- Dhaval ShahNewark$10K
- Jason PalopoliNewark$4K
- Bushra WaseemLewes$3K
- Jamal MislehNewark$2K
- Evan LapinskyNewark$2K
- Sumukh Arun KumarDover$2K
- Kathiresan SuppiahNewark$2K
- Nicole LaslettNewark$1K
- Sujung ParkNewark$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.